Browsing by Author "Briassoulis, E. Ch"
Now showing items 41-60 of 77
-
Article
Is the combination of 5-fluorouracil and folinic acid effective in advanced gastric carcinoma? Results of a pilot study and review of the literature
Pavlidis, Nicholas; Nikolaides, C.; Klouvas, G. D.; Briassoulis, E. Ch (1994)The main purpose of this trial was to investigate the activity of a less toxic regimen in patients with advanced gastric carcinoma regarding response rate and survival. We report on a pilot study of 20 patients treated ...
-
Article
Matrix metalloproteinases in carcinoma of unknown primary
Karavasilis, V.; Malamou-Mitsi, Vassiliki D.; Briassoulis, E. Ch; Tsanou, E.; Kitsou, E.; Kalofonos, H. P.; Fountzilas, George; Fotsis, T.; Pavlidis, Nicholas (2005)BACKGROUND. The purpose was to study proteolysis-related molecules, matrix metalloproteinase-2 (MMP-2) and MMP-9 and tissue inhibitor of metalloproteinases-1 (TIMP-1), in carcinoma of unknown primary (CUP). METHODS. ...
-
Article
Megestrol activity in recurrent adult type granulosa cell tumour of the ovary [2]
Briassoulis, E. Ch; Karavasilis, V.; Pavlidis, Nicholas (1997)
-
Article
Metastatic breast carcinoma confined to bone: Portrait of a clinical entity
Briassoulis, E. Ch; Karavasilis, V.; Kostadima, Lida; Ignatiadis, M.; Fountzilas, George; Pavlidis, Nicholas (2004)BACKGROUND. The current study was performed to study metastatic breast carcinoma that remains confined to bone. METHODS. The medical notes of 2514 breast carcinoma patients who were treated in 2 academic units over a 20-year ...
-
Article
Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: A hellenic cooperative oncology group study
Briassoulis, E. Ch; Fountzilas, George; Bamias, A. T.; Dimopoulos, M. A.; Xiros, N.; Aravantinos, Gerasimos; Samantas, E.; Kalofonos, H. P.; Makatsoris, T.; Mylonakis, N.; Papakostas, P.; Skarlos, Dimosthenis V.; Varthalitis, I.; Pavlidis, Nicholas (2008)Background: Cancer of unknown primary (CUP) lacks established therapy although it affects 3% of cancer patients. We evaluated the irinotecan- oxaliplatin combination (IROX regimen) in previously untreated patients with ...
-
Article
Near-absolute expression of the bcl-2 protein identifies a subgroup of stage II breast cancer patients with a most favorable outcome. Results of a clinicopathological study
Briassoulis, E. Ch; Agnantis, Niki J.; Zagorianakou, P.; Kamina, S.; Gorezi, M.; Pavlidis, Nicholas; Bai, M. C. (2001)The clinical relevance of quantitative assessment of tumor-tissue expression of the bcl-2 protein in operated stage II breast cancer was investigated in this study. Thirty-five cases were studied by immunohistochemistry ...
-
Article
The neutrophil, not the tumor: Serum CA 15-3 elevation as a result of granulocyte-colony-stimulating factor-induced neutrophil MUC1 overexpression and neutrophilia in patients with breast carcinoma receiving adjuvant chemotherapy
Pentheroudakis, George; Malamou-Mitsi, Vassiliki D.; Briassoulis, E. Ch; Damala, K.; Vassou, A.; Vartholomatos, G.; Kolaitis, N.; Pavlidis, Nicholas (2004)BACKGROUND. Patients with resected breast carcinoma who received granulocyte-colony-stimulating factor (G-CSF)-supported adjuvant chemotherapy exhibited an increase in their serum CA 15-3 levels. The authors investigated ...
-
Article
No response or survival improvement in small cell lung cancer after sequential chemotherapy with three non-cross resistant drug regimens - a pilot study
Pavlidis, Nicholas; Ch, F. Tolis; Briassoulis, E. Ch; Sourla, A.; Klouvas, G. D. (1991)In a pilot phase II study we have treated 25 patients with small cell lung cancer by utilizing 3 non-cross resistant drug regimens given in a sequential fashion in combination with radiotherapy to the primary tumor. VAC ...
-
Article
Noncardiogenic pulmonary edema: An unusual and serious complication of anticancer therapy
Briassoulis, E. Ch; Pavlidis, Nicholas (2001)Noncardiogenic pulmonary edema (NCPE) is a rare and less well-recognizable pulmonotoxic syndrome of anticancer therapy than pneumonitis/fibrosis. NCPE is a clinical syndrome characterized by simultaneous presence of severe ...
-
Article
Original article: Subsets of tumors responsive to cisplatin or carboplatin combinations in patients with carcinoma of unknown primary site: A hellenic cooperative oncology group study
Pavlidis, Nicholas; Kosmidis, Paraskevas A.; Skarlos, Dimosthenis V.; Briassoulis, E. Ch; Beer, M.; Theoharis, D.; Bafaloukos, Dimitrios; Maravegias, A.; Fountzilas, George (1992)Summary: In this retrospective analysis 48 patients with metastatic undifferentiated carcinoma, adenocarcinoma and epidermoid carcimona of unknown origin were studied. The purpose of this analysis was to evaluate both the ...
-
Article
Overexpression of C-myc, ras and C-erb B-2 oncoproteins in carcinoma of unknown primary origin
Pavlidis, Nicholas; Briassoulis, E. Ch; Bai, M. C.; Fountzilas, George; Agnantis, Niki J. (1995)The role of oncogenes in carcinoma of unknown primary site (CUP) has not yet been elucidated. In the present study the expression of the c-myc p62, ras p21 and c-erb B p185 oncoproteins were studied by a 3-step immunoperoxidase ...
-
Article
Oxaliplatin (eloxatin™) plus irinotecan combination chemotherapy found effective in refractory metastatic insular thyroid carcinoma
Briassoulis, E. Ch; Rontogianni, D.; Karavasilis, V.; Pavlidis, Nicholas (2005)Therapeutic options for metastatic insular thyroid carcinoma (ITC) are very limited. We present the case of a 39-year-old woman with refractory metastatic ITC who responded to oxaliplatin plus irinotecan chemotherapy. She ...
-
Article
p53/MDM-2 immunohistochemical expression correlated with proliferative activity in different subtypes of human sarcomas: A ten-year follow-up study
Stefanou, D. G.; Nonni, A. V.; Agnantis, Niki J.; Athanasiadou, S. E.; Briassoulis, E. Ch; Pavlidis, Nicholas (1998)The aim of this study was the evaluation of p53/MDM-2 protein overexpression in different subtypes of human sarcomas, and their correlation with proliferative activity and patient outcome. We selected 40 cases of human ...
-
Article
Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: A phase I/II study conducted by the Hellenic Cooperative Oncology Group
Fountzilas, George; Pectasides, Dimitrios; Kalogera-Fountzila, Anna; Skarlos, Dimosthenis V.; Kalofonos, H. P.; Papadimitriou, C.; Bafaloukos, Dimitrios; Lambropoulos, S.; Papadopoulos, S.; Kourea, H.; Markopoulos, C.; Linardou, H.; Mavroudis, D.; Briassoulis, E. Ch; Pavlidis, Nicholas; Razi, E. D.; Kosmidis, Paraskevas A.; Gogas, H. (2005)Paclitaxel (TaxolR) and carboplatin are an effective combination regimen for treating advanced breast cancer. Gefitinib (IRESSA) is the first epidermal growth factor receptor tyrosine kinase inhibitor to be approved for ...
-
Article
Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the hellenic cooperative oncology group
Fountzilas, George; Athanasiades, A.; Kalogera-Fountzila, Anna; Aravantinos, Gerasimos; Bafaloukos, Dimitrios; Briassoulis, E. Ch; Dombros, N.; Loannidis, I.; Pavlidis, Nicholas; Kosmidis, Paraskevas A.; Skarlos, Dimosthenis V. (1997)37 patients with advanced breast cancer resistant to anthracyclines were treated with paclitaxel 200 mg/m2 by 3-h infusion and carboplatin at an area under the curve of 7 mg · min/ml every 4 weeks with G-CSF support. There ...
-
Article
Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck: A phase II study conducted by the Hellenic Cooperative Oncology Group
Fountzilas, George; Skarlos, Dimosthenis V.; Athanasiades, A.; Kalogera-Fountzila, Anna; Samantas, E.; Bacoyiannis, Charalambos; Nicolaou, A.; Dombros, N.; Briassoulis, E. Ch; Dinopoulou, M.; Stathopoulos, G. P.; Pavlidis, Nicholas; Kosmidis, Paraskevas A.; Daniilidis, J. (1997)Background: Paclitaxel has been demonstrated to have significant activity in recurrent or metastatic head and neck cancer (HNC). In addition, the combination of paclitaxel and cisplatin is active in untreated patients with ...
-
Article
Paclitaxel in combination with carboplatin or gemcitabine for the treatment of advanced head and neck cancer
Fountzilas, George; Athanasiades, A.; Kalogera-Fountzila, Anna; Samantas, E.; Bacoyiannis, Charalambos; Briassoulis, E. Ch; Pavlidis, Nicholas; Kosmidis, Paraskevas A.; Skarlos, Dimosthenis V. (1997)We performed a phase II study to evaluate the activity and toxicity of the combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin as first-line treatment in patients with recurrent ...
-
Article
Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: Results of a dose-escalation study
Briassoulis, E. Ch; Karavasilis, V.; Tzamakou, E.; Haidou, C.; Piperidou, C.; Pavlidis, Nicholas (2002)We characterized the toxicity and determined the maximum tolerated dose of non-break weekly paclitaxel (Taxol) in chemotherapy-naive cancer patients, and studied pharmacokinetics of the formulation vehicle Cremophor-EL ...
-
Article
Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study
Pappas, P.; Karavasilis, V.; Briassoulis, E. Ch; Pavlidis, Nicholas; Marselos, M. (2005)Aim: To evaluate the pharmacokinetics of imatinib mesylate (Glivec) and its main metabolite (CGP74588) in a patient with end stage renal disease on hemodialysis and compare it with published data from subjects with normal ...
-
Article
Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer
Briassoulis, E. Ch; Samantas, E.; Kalofonos, H. P.; Skarlos, Dimosthenis V.; Makatsoris, T.; Christodoulou, C.; Fountzilas, George; Bamias, A. T.; Dimopoulos, M. A.; Kosmidis, Paraskevas A.; Pavlidis, Nicholas (2005)The irinotecan-cisplatin combination has emerged as a new standard for the treatment of advanced-stage small-cell lung cancer (AS-SCLC). To move forward we developed a 3-day regimen of cisplatin, etoposide and irinotecan. ...